Avalon Globocare (AVCO) versus Exponent (EXPO) Critical Survey

Share on StockTwits

Avalon Globocare (OTCMKTS:AVCO) and Exponent (NASDAQ:EXPO) are both business services companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Dividends

Exponent pays an annual dividend of $0.52 per share and has a dividend yield of 1.0%. Avalon Globocare does not pay a dividend. Exponent pays out 48.6% of its earnings in the form of a dividend. Exponent has increased its dividend for 5 consecutive years.

Profitability

This table compares Avalon Globocare and Exponent’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Avalon Globocare -365.09% -81.16% -44.88%
Exponent 13.98% 20.92% 14.34%

Insider & Institutional Ownership

88.1% of Exponent shares are owned by institutional investors. 75.0% of Avalon Globocare shares are owned by insiders. Comparatively, 2.7% of Exponent shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Avalon Globocare and Exponent’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Avalon Globocare $1.08 million 210.55 -$3.46 million N/A N/A
Exponent $347.80 million 7.77 $41.30 million $1.07 48.57

Exponent has higher revenue and earnings than Avalon Globocare.

Volatility & Risk

Avalon Globocare has a beta of -2.03, suggesting that its share price is 303% less volatile than the S&P 500. Comparatively, Exponent has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Avalon Globocare and Exponent, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avalon Globocare 0 0 0 0 N/A
Exponent 0 0 3 0 3.00

Exponent has a consensus target price of $40.00, suggesting a potential downside of 23.03%. Given Exponent’s higher probable upside, analysts plainly believe Exponent is more favorable than Avalon Globocare.

Summary

Exponent beats Avalon Globocare on 11 of the 14 factors compared between the two stocks.

Avalon Globocare Company Profile

Avalon GloboCare Corp., together with its subsidiaries, engages in integrating and managing healthcare services and resources in the United States. It provides medical related consulting services and develops Avalon Cell and Avalon Rehab platforms that cover the areas of regenerative medicine, cell-based immunotherapy, and exosome technology, as well as rehabilitation medicine. The company also develops proprietary diagnostic and therapeutic products leveraging exosome technology; and markets and distributes proprietary exosome isolation systems and related products to hospitals, as well as provides development services for hospitals. In addition, it owns and operates real property. The company has a strategic partnership Weill Cornell Medical College to co-develop technologies and bio-production of chimeric antigen receptor-T Therapy. Avalon GloboCare Corp. is headquartered in Freehold, New Jersey.

Exponent Company Profile

Exponent, Inc., together with its subsidiaries, operates as a science and engineering consulting company worldwide. Its services include analysis of product development, product recall, regulatory compliance, and the discovery of potential problems related to products, people, property, and impending litigation. The company operates in two segments, Engineering and Other Scientific, and Environmental and Health. The Engineering and Other Scientific segment provides services in the areas of biomechanics, biomedical engineering, buildings and structures, civil engineering, construction consulting, electrical engineering and computer science, human factors, industrial structures, materials and corrosion engineering, mechanical engineering, polymer science and materials chemistry, statistical and data sciences, thermal sciences, and vehicle analysis. The Environmental and Health segment offers services in the areas of chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences, and health sciences. The company offers approximately 90 different technical disciplines to solve complicated issues facing industry and government. It serves clients in chemical, construction, consumer products, energy, food, beverage and nutrition, government, life sciences, insurance, manufacturing, technology, industrial equipment, transportation, and other sectors of the economy. The company was formerly known as The Failure Group, Inc. and changed its name to Exponent, Inc. in 1998. Exponent, Inc. was founded in 1967 and is headquartered in Menlo Park, California.

Receive News & Ratings for Avalon Globocare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalon Globocare and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Solar Capital Ltd.  Shares Sold by Morgan Stanley
Solar Capital Ltd. Shares Sold by Morgan Stanley
M Holdings Securities Inc. Increases Stake in PepsiCo, Inc.
M Holdings Securities Inc. Increases Stake in PepsiCo, Inc.
Morgan Stanley Raises Stake in Just Energy Group Inc
Morgan Stanley Raises Stake in Just Energy Group Inc
Invesco CEF Income Composite ETF  Plans Monthly Dividend of $0.15
Invesco CEF Income Composite ETF Plans Monthly Dividend of $0.15
Invesco BulletShares 2020 High Yield Corporate Bond ETF Announces Monthly Dividend of $0.09
Invesco BulletShares 2020 High Yield Corporate Bond ETF Announces Monthly Dividend of $0.09
Invesco Multi-Factor Defensive Core Fixed Income ETF Declares Monthly Dividend of $0.06
Invesco Multi-Factor Defensive Core Fixed Income ETF Declares Monthly Dividend of $0.06


© 2006-2019 Ticker Report